← All Posts
BIO
BioMarin Pharmaceutical Inc.
June 03, 2026
•
Author: Phil Ratcliff
| Item |
Proposal |
Vote |
| 1 |
To elect the ten nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the next Annual Meeting and until their successors are duly elected and qualified |
|
| 1a |
Elizabeth McKee Anderson |
✓ For(5.607)
|
| 1b |
Barbara W. Bodem |
✓ For(5.607)
|
| 1c |
Ian T. Clark |
✓ For(5.607)
|
| 1d |
Athena Countouriotis, M.D. |
✓ For(5.607)
|
| 1e |
Willard Dere, M.D. |
✓ For(5.607)
|
| 1f |
Mark J. Enyedy |
✓ For(5.607)
|
| 1g |
Alexander Hardy |
✗ Against(5.607)
|
| 1h |
Maykin Ho, Ph.D. |
✓ For(5.607)
|
| 1i |
Robert J. Hombach |
✓ For(5.607)
|
| 1j |
Timothy P. Walbert |
✓ For(5.607)
|
| 2 |
To ratify the selection of KPMG LLP (KPMG) as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2026 |
✓ For(5.607)
|
| 3 |
To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers (NEOs) as disclosed in the Proxy Statement |
✓ For(5.607)
|
| 4 |
To approve an amendment to the 2017 Equity Incentive Plan, as amended |
✓ For(5.607)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial